Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript
Emergent BioSolutions Inc. ( EBS ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Frank Vargo Joseph Papa - CEO, President & Director Richard Lindahl - Executive VP, CFO & Treasurer Conference Call Participants Jessica Fye - JPMorgan Chase & Co, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $1.37 per share a year ago.
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
Emergent BioSolutions delivered a strong Q2 2025, beating its own guidance and showing major improvements in margins. EBS has a sound turnaround strategy that is showing signs of success. The company has some competitive advantages to maintain and grow market share.
Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Joseph C. Papa - CEO, President & Director Richard S.
Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
Emergent stock is down >40% since my last update. I had given the stock a "Buy" rating but noted that 2025 may be a difficult year. Emergent's MCM business has performed well, but Narcan sales fell drastically in Q1. Management believes revenues will increase in the second half of the year and expects to generate a net income of $750m–$850m of revenues in 2025.
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by.
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Officer Richard Lindahl - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Nick Richitt - JPMorgan Brandon Folkes - Rodman & Renshaw Operator Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call.
Emergent Biosolutions (EBS) Q4 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock.
Why Emergent BioSolutions Stock Blasted Higher Today
An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
